Literature DB >> 6489435

Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants.

D J Pettibone, J A Totaro, A B Pflueger.   

Abstract

The peripheral administration of tetrabenazine (TBZ) induces rapid depletion of brain regional concentrations of norepinephrine (NE), dopamine (DA) and serotonin (5-HT). With respect to both dosage and time, striatal DA was most sensitive to the effects of TBZ while hypothalamic NE was least affected. Pretreatment with the monoamine oxidase (MAO)-inhibitor, clorgyline (1-6 mg/kg) dose-dependently prevented the reduction of all three monoamines for up to 60 min after TBZ (3 mg/kg). The TBZ-induced depletion of cortical NE was also significantly antagonized by desmethylimipramine (DMI) but was of shorter duration (up to 30 min after TBZ). DMI, however, did not influence the effect of TBZ on striatal DA or hypothalamic 5-HT. The protective effects of both clorgyline and DMI were also evident under the conditions of the behavioral TBZ test utilizing high doses of TBZ (20 mg/kg).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6489435     DOI: 10.1016/0014-2999(84)90562-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  30 in total

1.  Tetrabenazine: for chorea associated with Huntington's disease.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

2.  Selection of sucrose concentration depends on the effort required to obtain it: studies using tetrabenazine, D1, D2, and D3 receptor antagonists.

Authors:  Marta Pardo; Laura López-Cruz; Noemí San Miguel; John D Salamone; Mercè Correa
Journal:  Psychopharmacology (Berl)       Date:  2015-02-03       Impact factor: 4.530

Review 3.  Therapeutic approaches to Huntington disease: from the bench to the clinic.

Authors:  Nicholas S Caron; E Ray Dorsey; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2018-09-21       Impact factor: 84.694

4.  Reserpine augmentation of desipramine in refractory depression: clinical and neurobiological effects.

Authors:  L H Price; D S Charney; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity.

Authors:  Kelly M Lohr; Kristen A Stout; Amy R Dunn; Minzheng Wang; Ali Salahpour; Thomas S Guillot; Gary W Miller
Journal:  ACS Chem Neurosci       Date:  2015-03-09       Impact factor: 4.418

Review 6.  Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.

Authors:  Kelly M Lohr; Shababa T Masoud; Ali Salahpour; Gary W Miller
Journal:  Eur J Neurosci       Date:  2016-09-02       Impact factor: 3.386

Review 7.  Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.

Authors:  Robert D Wyse; Gary L Dunbar; Julien Rossignol
Journal:  Int J Mol Sci       Date:  2014-01-23       Impact factor: 5.923

8.  Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine.

Authors:  Anthony Raffo; Kolbe Hancock; Teresa Polito; Yuli Xie; Gordon Andan; Piotr Witkowski; Mark Hardy; Pasquale Barba; Caterina Ferrara; Antonella Maffei; Matthew Freeby; Robin Goland; Rudolph L Leibel; Ian R Sweet; Paul E Harris
Journal:  J Endocrinol       Date:  2008-07       Impact factor: 4.286

Review 9.  Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology.

Authors:  John D Salamone; Samantha E Yohn; Laura López-Cruz; Noemí San Miguel; Mercè Correa
Journal:  Brain       Date:  2016-05       Impact factor: 13.501

10.  Tetrabenazine in the treatment of Huntington's disease.

Authors:  Diana Paleacu
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.